Other scientific networks

FIMM is an active member of the International Common Disease Alliance (ICDA) and the Nordic Society of Human Genetics and Precision Medicine.
International Common Disease Alliance

International Common Disease Alliance (ICDA) aims to improve prevention, diagnosis, and treatment of common diseases by accelerating discovery from genetic maps to biological mechanisms to physiology and medicine, to benefit people around the world. It is a scientific forum comprising international stakeholders across academia, medicine, biopharma, tech companies, and funders, spanning the breadth of relevant scientific disciplines. ICDA aims to include and serve the diverse range of the human population.

Mark Daly is one the 30 members of the ICDA Organizing Committee. 

Nordic Society of Human Genetics and Precision Medicine

The Nordic Society of Human Genetics and Precision Medicine (NSHG-PM) was created in order to: 

  • establish a Nordic framework for research into the genetics of human diseases, as well as into human evolution and population history;
  • accelerate discovery of disease susceptibility genes and genes protecting from disease through integrated analyses using multiple large-scale datasets and a range of experimental designs;
  • translate these findings so that they can be used for precision medicine to improve public health;
  • and uphold and promote the highest legal, regulatory, social, and ethical standards. 

Samuli Ripatti and Aarno Palotie are NSHG-PM council members.

The Nordic Alliance for Clinical Genomics

The Nordic Alliance for Clinical Genomics (NACG) is an independent, non-governmental, not-for-profit Nordic association. NACG partners work together and learn from each other to lift performance standards. NACG comes together in a series of workshops for hands-on discussions and activities, with updates on national developments.

NACG aims to:

  • Facilitate the responsible sharing of genomic data, bioinformatics tools, sequencing methods and best practices for interpretation of genomic data.
  • Enhance quality of genomic data and processes, and explore methodologies to provide assurance.
  • Understand legal barriers to the implementation of personalised medicine and to engage with key stakeholders that influence these barriers
  • Develop demonstration projects that challenge perceived legal barriers that limit responsible and ethical sharing of genomic and health data.
  • Build bridges between research and clinical communities, technologies and practices to foster innovation